Key Points
- Kestra Medical Technologies CFO Vaseem Mahboob sold 26,287 shares at an average price of $25.88, generating approximately $680,308. The sale reduced his direct ownership by 30.25% to 60,609 shares.
- KMTS reported quarterly revenue of $28.64 million but posted an EPS loss of $0.67, missing the consensus estimate of a $0.59 loss; analysts expect a full-year loss of $2.29 per share.
- Analyst sentiment is mixed, with four Buy, two Hold, and one Sell rating. The stock has an average consensus rating of Hold and a target price of $28.14, while shares recently traded at $27.90.
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) CFO Vaseem Mahboob sold 26,287 shares of the firm's stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $25.88, for a total value of $680,307.56. Following the completion of the sale, the chief financial officer directly owned 60,609 shares of the company's stock, valued at $1,568,560.92. The trade was a 30.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Vaseem Mahboob also recently made the following trade(s):
- On Tuesday, August 4th, Vaseem Mahboob sold 6,995 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $24.68, for a total value of $172,636.60.
- On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $23.80, for a total value of $128,305.80.
- On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.61, for a total value of $199,352.37.
- On Thursday, July 30th, Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.75, for a total transaction of $90,545.00.
Kestra Medical Technologies Trading Down 1.6%
KMTS stock opened at $27.90 on Wednesday. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a twelve month low of $14.40 and a twelve month high of $30.00. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -11.53 and a beta of 0.58. The firm's fifty day simple moving average is $23.31 and its two-hundred day simple moving average is $22.63.
Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last released its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The firm had revenue of $28.64 million during the quarter. As a group, analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on KMTS. Wall Street Zen upgraded Kestra Medical Technologies from a "sell" rating to a "hold" rating in a research report on Saturday. BTIG Research increased their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Wednesday, July 15th. JPMorgan Chase & Co. began coverage on Kestra Medical Technologies in a research note on Monday. They set an "overweight" rating and a $30.00 price target for the company. Oppenheimer started coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They issued a "market perform" rating on the stock. Finally, Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research note on Wednesday, July 15th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $28.14.
Read Our Latest Report on KMTS
Institutional Trading of Kestra Medical Technologies
Large investors have recently modified their holdings of the company. Seven Grand Managers LLC purchased a new stake in Kestra Medical Technologies in the fourth quarter worth about $2,652,000. Eventide Asset Management LLC increased its position in Kestra Medical Technologies by 5.4% during the 4th quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company's stock valued at $33,671,000 after purchasing an additional 65,288 shares during the period. Sei Investments Co. raised its holdings in shares of Kestra Medical Technologies by 22.6% in the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company's stock valued at $4,726,000 after purchasing an additional 43,753 shares in the last quarter. Summit Partners Public Asset Management LLC purchased a new stake in shares of Kestra Medical Technologies in the 4th quarter worth approximately $9,282,000. Finally, UBS Group AG boosted its stake in shares of Kestra Medical Technologies by 34.9% during the fourth quarter. UBS Group AG now owns 270,058 shares of the company's stock valued at $7,162,000 after purchasing an additional 69,908 shares in the last quarter.
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
